Glaxosmithkline Pharma Peer Comparison
NSE: GLAXO | BSE: 500660
₹3,069.10
As on 27-Aug-2026IST
Market cap
₹52,051 Cr
Revenue (TTM)
₹3,955 Cr
P/E Ratio
48.7
P/B Ratio
20.7
Div. Yield
1.9 %
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
52,051 | 1,18,244 | 98,980 | 98,254 | 98,939 |
Revenue (₹ Cr) |
3,955 | 28,592 | 29,967 | 33,228 | 14,738 |
Net Profit (₹ Cr) |
1,068.15 | 4,492.20 | 5,551.01 | 3,169.30 | 2,055.11 |
Net Margin (%) |
26.05 | 14.92 | 18.23 | 9.15 | 13.64 |
RoE (%) |
52.98 | 18.78 | 28.32 | 8.72 | 13.60 |
Price to Earnings |
48.73 | 26.20 | 17.90 | 30.49 | 48.44 |
Price-To-Book |
20.65 | 4.39 | 4.16 | 2.57 | 5.88 |
Income Statement (₹ Cr)
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
3,954.94 | 28,591.70 | 29,966.58 | 33,227.90 | 14,737.88 |
|
Total Income
|
4,100.34 | 30,111.40 | 30,442.31 | 34,650.70 | 15,061.79 |
|
Total Expenditure
|
2,601.44 | 21,334.70 | 20,428.27 | 28,088.10 | 10,911.05 |
|
EBITDA
|
1,353.50 | 7,257.00 | 9,538.31 | 5,139.80 | 3,826.83 |
|
Depreciation
|
66.76 | 1,724.60 | 1,529.37 | 2,119.30 | 893.20 |
|
EBIT
|
1,286.74 | 5,532.40 | 8,008.94 | 3,020.50 | 2,933.63 |
|
Interest
|
3.28 | 510.20 | 452.37 | 416.30 | 578.61 |
|
Other Income
|
145.40 | 1,519.70 | 475.73 | 1,422.80 | 323.91 |
|
Exceptional Items
|
20.62 | -534.80 | -557.91 | 0.00 | -129.75 |
|
Profit before Tax
|
1,449.48 | 6,007.10 | 7,474.39 | 4,027.00 | 2,549.18 |
|
Provision for Tax
|
381.33 | 1,514.90 | 1,923.38 | 857.70 | 494.07 |
|
Profit after Tax
|
1,068.15 | 4,492.20 | 5,551.01 | 3,169.30 | 2,055.11 |
Liabilities (₹ Cr)
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,267.42 | 27,111.40 | 22,448.27 | 37,891.50 | 16,300.34 |
|
Minority Interest
|
0.00 | -79.70 | -22.18 | 38.90 | -24.90 |
|
Non-Current Liabilities
|
277.34 | 7,112.50 | 3,200.22 | 3,145.10 | 5,011.23 |
|
Current Liabilities
|
1,779.11 | 15,711.90 | 12,651.24 | 16,747.40 | 6,507.25 |
|
Total Liabilities
|
4,323.87 | 50,672.60 | 38,146.06 | 56,576.70 | 27,754.83 |
Assets (₹ Cr)
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
416.63 | 31,677.20 | 11,888.82 | 27,204.00 | 20,274.65 |
|
Current Assets
|
3,606.18 | 19,906.10 | 24,027.38 | 30,179.30 | 6,954.20 |
|
Total Assets
|
4,323.87 | 50,672.60 | 38,146.06 | 56,576.70 | 27,754.83 |
|
Total Debt*
|
0.00 | 11,769.50 | 5,910.20 | 7,734.10 | 6,021.78 |
|
Net Current Assets
|
1,827.07 | 4,194.20 | 11,376.14 | 13,431.90 | 446.95 |
|
Contingent Liabilities
|
515.18 | 989.90 | 1,094.02 | 336.14 | 924.77 |
Cashflow (₹ Cr)
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
903.30 | 2,116.60 | 7,334.50 | 5,673.70 | 3,121.29 |
|
Cash Flow from Investing Activities
|
396.98 | -8,296.10 | -3,864.59 | -6,549.30 | -196.42 |
|
Cash from Financing Activities
|
-737.08 | 5,806.90 | -845.87 | 829.00 | -2,952.69 |
|
Net Cash Inflow / Outflow
|
563.20 | -372.60 | 2,624.04 | -46.60 | -27.82 |
Ratios
Profitability Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
66.79 | 21.39 | 28.86 | 13.75 | 13.24 |
|
ROE (%)
|
52.98 | 18.78 | 28.32 | 8.72 | 13.60 |
|
ROA (%)
|
25.34 | 10.03 | 16.43 | 5.89 | 7.36 |
|
EBIT Margin (%)
|
32.54 | 19.35 | 26.73 | 9.09 | 19.91 |
|
Net Margin (%)
|
26.05 | 14.92 | 18.23 | 9.15 | 13.64 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
5.75 | 21.11 | 28.19 | -0.87 | 14.16 |
|
EBIT Growth (%)
|
13.66 | -8.99 | 77.03 | -55.06 | 19.45 |
|
Net Profit Growth (%)
|
12.41 | -3.14 | 49.13 | -44.66 | 8.09 |
|
EPS Growth (%)
|
11.21 | 4.31 | 60.86 | -43.29 | 12.27 |
|
Book Value Growth (%)
|
16.12 | 13.19 | 30.75 | 12.99 | 13.74 |
Valuation Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
49.43 | 24.19 | 16.60 | 30.49 | 46.04 |
|
Price / Book Value
|
20.65 | 4.39 | 4.16 | 2.57 | 5.88 |
|
Dividend Yield (%)
|
1.85 | 0.08 | 0.83 | 0.68 | 0.04 |
|
EV/EBITDA
|
36.40 | 16.92 | 10.03 | 19.25 | 26.90 |
|
Market Cap (₹ Cr)
|
38,682.23 | 87,643.18 | 1,05,737.27 | 1,04,763.81 | 82,801.75 |
Solvency Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.12 | 0.07 | 0.00 | 0.17 |
|
Short term debt to equity ratio
|
-- | 0.16 | 0.18 | 0.16 | 0.04 |
|
Current Ratio
|
2.03 | 1.27 | 1.90 | 1.80 | 1.07 |
|
Quick Ratio
|
1.77 | 0.91 | 1.42 | 1.35 | 0.74 |
|
Interest Coverage
|
442.91 | 12.77 | 17.52 | 10.67 | 5.41 |
Operating Efficiency Ratios
| Glaxosmithkline Pharma | Zydus Lifesciences | Lupin | Dr. Reddy'S Labs | Mankind Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
6.91 | 18.94 | 22.04 | 30.47 | 11.74 |
|
Asset Turnover
|
0.94 | 0.64 | 0.89 | 0.62 | 0.53 |
|
Receivable days
|
24.45 | 33.55 | 51.23 | 103.79 | 39.93 |
|
Inventory Days
|
40.60 | 33.80 | 48.93 | 79.94 | 51.78 |
|
Payable days
|
172.70 | 149.82 | 205.75 | 84.78 | 111.46 |
|
Cash Conversion Cycle
|
-107.65 | -82.46 | -105.59 | 98.95 | -19.75 |